Kriya Therapeutics Secures $313 Million to Advance Gene Therapy Pipeline

DURHAM, N.C. August 24, 2025– Kriya Therapeutics, a biopharmaceutical company focused on gene therapies for chronic diseases, has raised $313.3 million in a new funding round. The financing, disclosed in a recent SEC filing, did not name the two participating investors but marks one of the largest private funding rounds in biopharma this year. The haul adds to Kriya’s previous raises, which include a $100 million Series B in 2021 and a $270 million Series C in 2022.

The new capital will be used to advance Kriya’s pipeline of single-dose gene therapies, which targets a wide range of chronic conditions. The company’s lead asset, KRIYA-825, is a gene therapy for geographic atrophy (GA), a common cause of vision loss. An adeno-associated virus (AAV)-based gene therapy, KRIYA-825 expresses a complement CR2-CR1 fusion protein—designed to inhibit the activity of complement C3 and C5—for the treatment of GA. Kriya’s KRIYA-825 was designed with the following goals in mind:

• Robust complement inhibition: A complement receptor 2-complement receptor 1 (CR2-CR1) fusion protein—where the CR1 domain is designed to block the activity of both complements C3 and C5, while the CR2 domain is designed to bind to the surfaces of cells where complement fragments deposit and cause damage.
• Multi-year durability: AAV-mediated continuous expression of CR2-CR1 fusion protein following a one-time injection to eliminate the need for frequent intravitreal injections that currently available therapies for GA require.
• Targeted delivery: A one-time suprachoroidal injection to achieve transduction of, and the delivery of therapeutic protein to, retinal cells while minimizing inflammation and overall patient burden.

Beyond its lead GA program, Kriya is also developing KRIYA-748 for trigeminal neuralgia, a condition that causes severe facial pain. The company’s pipeline also includes programs for thyroid eye disease, focal epilepsy, type 1 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).

Kriya’s successful fundraising comes at a time of significant scrutiny for the gene therapy space, which has faced recent regulatory and clinical setbacks. In recent months, the FDA has narrowed the coverage of bluebird bio’s gene therapy Skysona and has requested a temporary halt on shipments of Sarepta Therapeutics’ Duchenne muscular dystrophy treatment, Elevidys, following patient deaths.

Despite these industry-wide challenges, Kriya’s new funding places it among the top biotech funding rounds of 2025, just behind Isomorphic Labs ($600 million), Verdiva Bio, and Pathos AI.